New Anticancer Drugs: Reliably Assessing “Value” While Addressing High Prices

Countries face challenges in paying for new drugs. High prices are driven in part by exploding drug development costs, which, in turn, are driven by essential but excessive regulation. Burdensome regulation also delays drug development, and this can translate into thousands of life-years lost. We ne...

Celý popis

Podrobná bibliografie

Hlavní autoři:	David J. Stewart, John-Peter Bradford, Sandeep Sehdev, Tim Ramsay, Vishal Navani, Nigel S. B. Rawson, Di Maria Jiang, Joanna Gotfrit, Paul Wheatley-Price, Geoffrey Liu, Alan Kaplan, Silvana Spadafora, Shaun G. Goodman, Rebecca A. C. Auer, Gerald Batist
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2024-04-01
Edice:	Current Oncology
Témata:	drug costs drug value ICER QALY
On-line přístup:	https://www.mdpi.com/1718-7729/31/5/184
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!